Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that initial data from a study of the company's PaQ? Insulin Delivery Device were presented today at the 6th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Paris, France. The data suggest that PaQ is a safe, highly satisfying alternative to multiple daily insulin injections (MDI) for people with type 2 diabetes ? many of whom need new tools to help them achieve better glycemic control.
"This study demonstrated that simple infusion with a device such as PaQ is a valid approach for people with type 2 diabetes who are dependent on multiple daily insulin injections," said Dr. Julia Mader of the Division of Endocrinology and Metabolism, Medical University of Graz, who presented the data. "This is very exciting because it means we will have a new tool to help our patients with type 2 diabetes overcome some of the obstacles that currently prevent them from effectively managing their disease."
http://www.prnewswire.com/news-rele...ng-people-with-type-2-diabetes-193865071.html
"This study demonstrated that simple infusion with a device such as PaQ is a valid approach for people with type 2 diabetes who are dependent on multiple daily insulin injections," said Dr. Julia Mader of the Division of Endocrinology and Metabolism, Medical University of Graz, who presented the data. "This is very exciting because it means we will have a new tool to help our patients with type 2 diabetes overcome some of the obstacles that currently prevent them from effectively managing their disease."
http://www.prnewswire.com/news-rele...ng-people-with-type-2-diabetes-193865071.html